Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Berris van Kessel

Lenalidomide Combined With Low-Dose Cyclophosphamide and Prednisone Modulates Ikaros and Aiolos in Lymphocytes, Resulting in Immunostimulatory Effects in Lenalidomide-Refractory Multiple Myeloma Patients

Oncotarget

Oncology

2018

English

Inhibition of Protein Geranylgeranylation Induces Apoptosis in Myeloma Plasma Cells by Reducing McL-1 Protein Levels

English

Related publications

Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma

Hematology

2016

English

Lenalidomide−prednisone Induction Followed by Lenalidomide−melphalan−prednisone Consolidation and Lenalidomide−prednisone Maintenance in Newly Diagnosed Elderly Unfit Myeloma Patients

English

Proteasome Inhibitors Block Ikaros Degradation by Lenalidomide in Multiple Myeloma

Haematologica

Hematology

2015

English

Pembrolizumab Combined With Lenalidomide and Low‐dose Dexamethasone for Relapsed or Refractory Multiple Myeloma: Phase I KEYNOTE ‐023 Study

British Journal of Haematology

Hematology

2019

English

Lenalidomide Induced Stroke in Multiple Myeloma

English

Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

English

Update on the Role of Lenalidomide in Patients With Multiple Myeloma

Therapeutic Advances in Hematology

Hematology

2018

English

Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)

Hematological Oncology

English

GRP-024 Antithrombotic Prophylaxis in Patients With Multiple Myeloma Being Treated With Lenalidomide

European Journal of Hospital Pharmacy: Science and Practice

Pharmacy

2013

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Berris van Kessel

Lenalidomide Combined With Low-Dose Cyclophosphamide and Prednisone Modulates Ikaros and Aiolos in Lymphocytes, Resulting in Immunostimulatory Effects in Lenalidomide-Refractory Multiple Myeloma Patients

Inhibition of Protein Geranylgeranylation Induces Apoptosis in Myeloma Plasma Cells by Reducing McL-1 Protein Levels

Related publications

Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma

Lenalidomide−prednisone Induction Followed by Lenalidomide−melphalan−prednisone Consolidation and Lenalidomide−prednisone Maintenance in Newly Diagnosed Elderly Unfit Myeloma Patients

Proteasome Inhibitors Block Ikaros Degradation by Lenalidomide in Multiple Myeloma

Pembrolizumab Combined With Lenalidomide and Low‐dose Dexamethasone for Relapsed or Refractory Multiple Myeloma: Phase I KEYNOTE ‐023 Study

Lenalidomide Induced Stroke in Multiple Myeloma

Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Update on the Role of Lenalidomide in Patients With Multiple Myeloma

Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)

GRP-024 Antithrombotic Prophylaxis in Patients With Multiple Myeloma Being Treated With Lenalidomide